Compounds, compositions, and methods

A method for treating a disease or condition mediated, at least in part, by LRRK2, wherein the disease or condition is selected from the group consisting of kidney cancer, breast cancer, prostate cancer, blood cancer, papillary cancer, lung cancer, acute myelogenous leukemia, multiple myeloma, leprosy, Crohn's disease, inflammatory bowel disease, ulcerative colitis, rheumatoid arthritis, and ankylosing spondylitis, the method comprising administering to a subject in need thereof an effective amount of a compound of formula Ia:

• or a pharmaceutically acceptable salt, deuterated analog, prodrug, stereoisomer, or a mixture of stereoisomers thereof, wherein:
• R1 is optionally substituted cycloalkyl or C1-6 alkyl optionally substituted with halo;
• R2 is halo, cyano, optionally substituted C1-6 alkyl, optionally substituted C2-6 alkenyl, optionally substituted C2-6 alkynyl, optionally substituted cycloalkyl, optionally substituted C1-6 alkoxy, optionally substituted cycloalkoxy, optionally substituted C1-6 alkylthio, optionally substituted C1-6 alkylsulfonyl, —C(O)R10, or —C(O)N(R11)(R12);
• R3 is optionally substituted C1-6 alkoxy, optionally substituted cycloalkyl, optionally substituted cycloalkoxy, optionally substituted C1-6 alkylthio, optionally substituted C1-6 alkylsulfonyl, or —N(R11)(R12);
• R4 is hydrogen or halo;
• R6 and R7 are each independently hydrogen or C1-6 alkyl optionally substituted with halo;
• R8 and R9 are each independently hydrogen, cyano, halo, optionally substituted C1-6 alkyl, optionally substituted C1-6 alkoxy, or optionally substituted heteroaryl;
• R10 is optionally substituted C1-6 alkyl or optionally substituted C1-6 alkoxy;
• and
• R11 and R12 are each independently hydrogen, optionally substituted C1-6 alkyl, or optionally substituted cycloalkyl.